(53, 69) have identified that miR-106a and miR-27a enhanced radiotherapy sensitivity in HPV-positive HNSCC by targeting RUNX3 and SMG1 levels, respectively. This evidence concerns the gene RUNX3 and head and neck squamous cell carcinoma.